N-(2-methyl-5-nitrophenyl)-N-methylsulfonylmethanesulfonamide | 652129-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-methyl-5-nitrophenyl)-N-methylsulfonylmethanesulfonamide
• 英文别名: N-(2-methyl-5-nitrophenyl)-N-methylsulonylmethanesulonamide
• CAS: 652129-85-6
• 化学式: C₉H₁₂N₂O₆S₂
• 分子量: 308.336
• InChiKey: AANYHLKFVXTOAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  134
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-(2-methyl-5-nitrophenyl)-N-methylsulfonylmethanesulfonamide 在 三乙烯二胺 、 tris-(dibenzylideneacetone)dipalladium(0) 、 N-碘代丁二酰亚胺 、 氯化亚砜 、 水 、 sodium thiosulfate 、 溶剂黄146 、 potassium hydroxide 、 lithium hexamethyldisilazane 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.67h， 生成 N-[2-(2-cyanoacetyl)-5-methyl-1H-indol-6-yl]methanesulfonamide
  参考文献：
  名称：

  AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS

  摘要：

  公开号：

  EP3312172B1
• 作为产物：
  描述：

  甲基磺酰氯 、 2-氨基-4-硝基甲苯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.67h， 以38.0 g的产率得到N-(2-methyl-5-nitrophenyl)-N-methylsulfonylmethanesulfonamide
  参考文献：
  名称：

  AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS

  摘要：

  公开号：

  EP3312172B1

文献信息

• Methods of treating inflammation
  申请人：Epstein Paul

  公开号：US20090105281A1

  公开（公告）日：2009-04-23

  The invention features compositions and methods for treating inflammation and other immune-related disorders.
• Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)
  申请人：Insel Paul A.

  公开号：US20090131353A1

  公开（公告）日：2009-05-21

  The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
• Methods of Treating Inflammation
  申请人：Epstein Paul

  公开号：US20090239884A1

  公开（公告）日：2009-09-24

  The invention features compositions and methods for treating inflammation and other immune-related disorders.
• METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP
  申请人：Abraham Soman N.

  公开号：US20110171195A1

  公开（公告）日：2011-07-14

  Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof. In particular, the compositions and kits may also include at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs.
• METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY
  申请人：Whalen Anne

  公开号：US20110224128A1

  公开（公告）日：2011-09-15

  The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.